Efficacy and safety of ecolizumab for the treatment of hemolytic syndrome atypical uremic
AETSA
Record ID 32018000421
Spanish
Original Title:
Eculizumab en el tratamiento del síndrome hemolítico urémico atípico.
Authors' objectives:
To assess the efficacy, safety and efficiency of eculizumab in adults, adolescents and paediatric patients with atypical haemolytic-uremic syndrome (aHUS), both resistant and sensitive to plasma therapy.
To assess the efficacy of eculizumab taking into account predefined subgroups of patients.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
https://www.aetsa.org/publicacion/eculizumab-en-el-tratamiento-del-sindrome-hemolitico-uremico-atipico/
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
Country:
Spain
MeSH Terms
- Hemolytic-Uremic Syndrome
- Antibodies, Monoclonal, Humanized
- Atypical Hemolytic Uremic Syndrome
- Complement Inactivating Agents
Keywords
- Síndrome Hemolítico-Urémico
- Anticuerpos monoclonales
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
<p>Andalusian Agency for Health Technology Assessment (AETSA)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.